These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27591907)

  • 1. Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Ito H; Mizumoto T; Tempaku H; Fujinaga K; Sawada Y; Shimpo H
    J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1471-1478. PubMed ID: 27591907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Suehiro Y; Hosono M; Shibata T; Sasaki Y; Hirai H; Nakahira A; Kubota Y; Kaku D; Suehiro S
    Osaka City Med J; 2016 Dec; 62(2):111-119. PubMed ID: 30721586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short-term administration of tolvaptan after open heart surgery.
    Matsuyama K; Koizumi N; Nishibe T; Iwasaki T; Iwahasi T; Toguchi K; Takahashi S; Iwahori A; Maruno K; Ogino H
    Int J Cardiol; 2016 Oct; 220():192-5. PubMed ID: 27379922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
    Iwatani H; Kawabata H; Sakaguchi Y; Yamamoto R; Hamano T; Rakugi H; Isaka Y
    Nephron; 2015; 130(1):8-12. PubMed ID: 25926290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery.
    Katayama Y; Ozawa T; Shiono N; Masuhara H; Fujii T; Watanabe Y
    Gen Thorac Cardiovasc Surg; 2017 Nov; 65(11):622-626. PubMed ID: 28647800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.
    Kido T; Nishi H; Toda K; Ueno T; Kuratani T; Sakaki M; Takahashi T; Sawa Y
    Gen Thorac Cardiovasc Surg; 2017 Feb; 65(2):110-116. PubMed ID: 27645146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.
    Nishi H; Toda K; Miyagawa S; Yoshikawa Y; Fukushima S; Kawamura M; Yoshioka D; Saito T; Ueno T; Kuratani T; Sawa Y
    Surg Today; 2015 Dec; 45(12):1542-51. PubMed ID: 26411431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.
    Nakagawa A; Atsukawa M; Tsubota A; Kondo C; Okubo T; Arai T; Itokawa N; Narahara Y; Iwakiri K
    World J Gastroenterol; 2016 Jun; 22(21):5104-13. PubMed ID: 27275103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement.
    Iida Y; Yoshitake A; Shimizu H
    Ann Vasc Surg; 2019 Apr; 56():103-107. PubMed ID: 30342208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Tolvaptan in Patients with Volume Overload after Cardiac Surgery.
    Noguchi K; Tanaka M; Katayama I; Yamabe T; Yuji D; Oosiro N; Sirouzu M
    Heart Surg Forum; 2015 Nov; 18(6):E232-6. PubMed ID: 26726710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery.
    Yamada M; Nishi H; Sekiya N; Horikawa K; Takahashi T; Sawa Y
    Surg Today; 2017 Apr; 47(4):498-505. PubMed ID: 27553014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
    Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
    J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y
    Heart Vessels; 2016 Oct; 31(10):1650-8. PubMed ID: 26676672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound.
    Kato TS; Ono S; Kajimoto K; Kuwaki K; Yamamoto T; Amano A
    J Cardiothorac Surg; 2015 Nov; 10():143. PubMed ID: 26525900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Safety and Efficacy Study of Tolvaptan Following Open Heart Surgery in 109 Cases.
    Kono T; Tayama E; Hori H; Ueda T; Yamaki Y; Tanaka H
    Int Heart J; 2016 Jul; 57(4):496-502. PubMed ID: 27396557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin antagonist efficacy and safety in volume-overloaded critically ill patients: a new therapeutic alternative.
    Ruiz-Ramos J; Ramírez P; Broch MJ; Gordon M; Villarreal E; Pinos A; Sosa M; Castellanos-Ortega Á
    Eur J Hosp Pharm; 2020 May; 27(3):157-161. PubMed ID: 32419936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.